Our proprietary technology platform systematically leverages the powerful tools of big genomic data and AI to build molecular networks: a set of interconnected potential therapeutic targets.

Harnessing disease molecular networks, we screen both generic compounds and NCEs to develop novel drug combinations hitting multiple highly relevant disease targets.

Formulated with optimal doses of their components, our products are expected to be safer and more effective than existing therapies.